Announcement
21 Apr 2020
In April 2020, the Norwegian authorities introduced a notification requirement on exports of medications for obstructive pulmonary disease following the COVID-19 outbreak.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
21 Apr 2020
Revocation date:
31 Dec 2020
Updated: 21 Apr 2020
Export licensing requirement
On 21 April 2020, the Norwegian Medicines Agency introduced a notification requirement on exports of pharmaceutical drugs to treat obstructive pulmonary disease following the COVID-19 outbreak. The...
Sign in to see more
Related State Acts
03 Jul 2020
Norway: Introduction and subsequent termination of export ban on formoterol and budesonide (COVID-19)
20 May 2020
Norway: Introduction and subsequent termination of export ban on formoterol, glycopyrronium bromide and beclomethasone following the outbreak of COVID-19
11 May 2020
Norway: Introduction and subsequent termination of export ban on six pharmaceutical products following the outbreak of COVID-19
Threads
See all
This state act is not part of any Thread yet.